(NASDAQ: MTVA) Metavia's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.13%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.27%.
Metavia's earnings in 2025 is -$18,491,000.On average, 3 Wall Street analysts forecast MTVA's earnings for 2025 to be -$25,729,530, with the lowest MTVA earnings forecast at -$29,037,371, and the highest MTVA earnings forecast at -$21,052,094. On average, 3 Wall Street analysts forecast MTVA's earnings for 2026 to be -$18,794,438, with the lowest MTVA earnings forecast at -$27,101,546, and the highest MTVA earnings forecast at -$8,469,233.
In 2027, MTVA is forecast to generate -$25,528,688 in earnings, with the lowest earnings forecast at -$26,375,612 and the highest earnings forecast at -$24,681,765.